高端奶粉卖不动了？飞鹤股价大跌，上半年营收、净利全面下滑

Core Viewpoint - China Feihe's stock price plummeted significantly following a profit warning, indicating severe challenges in the high-end infant formula market due to various factors including demographic changes and increased competition [2][3][6] Financial Performance - For the first half of 2025, Feihe expects revenue between 9.1 billion to 9.3 billion yuan, representing a year-on-year decline of 8% to 10% [3] - The projected net profit for the same period is between 1 billion to 1.2 billion yuan, a staggering drop of 37% to 47% compared to the previous year [3][6] - In 2024, Feihe's revenue is anticipated to be 20.75 billion yuan, a 6% increase year-on-year, while net profit is expected to reach 3.65 billion yuan, an 11% increase [6] Market Challenges - The high-end infant formula market is facing multiple pressures, including a declining birth rate and changing consumer preferences, leading to a contraction in market size [7][8] - In 2023, China's birth rate fell to 6.5‰, with the infant formula market shrinking by 4% [7] - Although a slight recovery in birth rates is expected in 2024, the impact on the industry remains limited [7] Competitive Landscape - Feihe's pricing strategy is misaligned with consumer preferences, as the most popular price range for infant formula is 200-299 yuan, while Feihe's main products are priced at 350-450 yuan [8] - Competitors like Junlebao and Yili are gaining market share by offering products in more accessible price ranges, further squeezing Feihe's high-end positioning [8] Inventory and Channel Issues - Feihe has reduced channel inventory to maintain product freshness, which has contributed to revenue declines [10] - The company faces significant inventory pressure, leading to price discrepancies between online and offline sales channels [10] - A shift towards online purchasing among younger parents is necessitating a transformation in Feihe's distribution strategy [10] Strategic Initiatives - In response to the challenges, Feihe has announced a 1 billion yuan share buyback plan and committed to a minimum dividend of 2 billion yuan in 2025 to bolster market confidence [6] - The company is also diversifying its product offerings beyond infant formula, targeting areas such as maternal and child health, but infant formula remains its primary revenue source [10]